Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials
An erratum to this article was published (Crit Care, 27 Oct 2023 ↗)
Pooled resultResult — go to the resultRelative risk 0.61 95% CI 0.44–0.85Authors' conclusion
In patients with sCAP, adjunctive corticosteroids can provide survival benefits and improve clinical outcomes without increasing adverse events.
Study context
- Population
- Patients with severe community-acquired pneumonia (sCAP)
- Participants
- 1,689 patients
- Comparison
- Adjunctive systemic corticosteroids vs control
- Outcome
- All-cause mortality
- Follow-up
- 30 days
Pooled result
As reported in the abstract
Relative risk
0.61
95% CI 0.44–0.85
P < 0.01
Study vs Control
RR 0.61 (95% CI 0.44–0.85); P < 0.01
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Requirement of mechanical ventilation | 0.57 (0.45–0.73) | P < 0.001 | |
| 0.512Relative risk (log scale) |
| Outcome | MD (95% CI) | P value |
|---|---|---|
| ICU LOS | - 0.8 (- 1.4 to - 0.1) | P = 0.02 |
| Hospital LOS | - 1.1 (- 2.0 to - 0.1) | P = 0.04 |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Gastrointestinal tract bleeding | 1.03 (0.49–2.18) | P = 0.93 | |
| Healthcare-associated infection | 0.89 (0.60–1.32) | P = 0.56 | |
| AKI | 0.68 (0.21–2.26) | P = 0.53 | |
| 0.20.5125Relative risk (log scale) |
Original publication
Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. Published 8 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →